Hydroxy-chloroquine (HQ) is a cheap, safe and well-known drug that has been used for more than 70 years [@bib0005], [@bib0010]. It is widely used as anti-malarial agent and has established immunomodulatory and anti-inflammatory activity; it has also proven clinical efficacy against a large variety of viral infections by increasing endosomal pH required for virus replication [@bib0010]. Considering the public health emergency since the onset of the new coronavirus pandemic, repositioning of this molecule is an interesting strategy because pharmacokinetics, safety profile, posology and drug interactions of HQ are well known [@bib0015], [@bib0020], [@bib0025]. Many emerging evidences have converged on the efficacy of HQ in the treatment of Covid-19 infection [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045]. Multicenter clinical trials conducted in China showed apparent efficacy and acceptable safety against COVID-19 associated pneumonia [@bib0040]. In a recent series reported by Gautret et al. [@bib0045], the authors demonstrated that HQ treatment has a significant effect, both in terms of clinical outcome and viral clearance. At day 6 post-inclusion, 70% of hydroxychloroquine-treated patients were virologically cured comparing with 12.5% in the control group. Gautret et al. suggested that further works are needed to determine if HQ antiviral prophylaxis is useful, especially for healthcare workers [@bib0045].

We absolutely agree with this suggestion and believe that the HQ antiviral prophylaxis for healthcare workers should be considered and urgently assessed. Indeed, caregivers are in the frontline against the Covid-19 all around the world and are particularly exposed to Covid-19 infection. According to many reports, Thousands of nurses and doctors contracted the virus since the onset of the new coronavirus [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070]. In China, among the 44,672 cases, a total of 1716 were healthcare workers (3.8%), as of February 11, 2020 [@bib0050]. In Italy, as of March 20th, 2020, according to the country\'s National Health Institute, seventeen doctors have died from Covid-19 and there are at least 3654 healthcare workers that have been infected, representing 9% of total cases [@bib0055], [@bib0060], [@bib0065]. In Paris, France, as of March 20th, 2020, there were 345 healthcare workers infected by the Covid-19 [@bib0070]. And as of March 23rd, 2020, five doctors have died from Covid-19 in France [@bib0075], [@bib0080]. The number of infected healthcare workers is probably underestimated because they are not always tested [@bib0055].

Moreover, medical demography is increasingly aging in the OECD area (organization for economic cooperation and development area), 38% of doctors are over 55 [@bib0085]. In France, the mean age of doctors is 57 years and 41% of them over 60 [@bib0090]. Knowing that the morbidity and mortality rate from Covid-19 infection increases with age [@bib0050], it is to be feared that the human toll may be heavy among caregivers. As of March 23rd, 2020, the 5 died doctors in France were 60, 66, 67, 68 and 70 years old [@bib0075], [@bib0080].

The high rate of infections among healthcare staff is a serious concern because healthcare workers who are infected must stay away from work for at least 14 days, depleting the already exhausted workforce [@bib0055], [@bib0065], [@bib0095], [@bib0100]. In Iran, because of the lack of healthcare staff and the enormous number of patients, some nurses are forced to work 19 h per day [@bib0100], and this situation could be worsened if some of the remaining caregivers contract the infection. The more healthcare staff is infected, the weaker the responsiveness of the healthcare system, particularly in a context of a chronic shortage of staff and means [@bib0095], [@bib0100]. This vicious circle could increase mortality among Covid-19 hospitalized patients. It is important to preserve the healthcare reserve which is the back spine in the fight against Covid-19. This need is even more pressing in the developing countries where the medical demography is weaker, where the personal protection means as surgical and ffp2 masks are not sufficiently available and where any loss of this qualified workforce could have disastrous public health consequences.

Chemoprophylaxis is an established approach to potentially control infectious diseases and should be considered in the fight against COVID-19 pandemic [@bib0105]. Development of new vaccines and antivirals is time-consuming and expensive while the repositioning of available drugs should receive priority attention [@bib0105]. HQ has a long safety record, is inexpensive and widely available [@bib0010]. Considering that this drug is commonly prescribed in malaria prophylaxis when traveling to endemic malaria areas, and that this treatment can be prescribed for periods of up to several years [@bib0105], it would be logical to prescribe this molecule as prophylaxis for healthcare workers who are exposed to Covid-19, almost like when it is prescribed as prophylaxis for travelers to a malaria-endemic area. Moreover, antiviral prophylaxis would provide some psychological reinsurance that could reduce stress among caregivers who are at the forefront of the fight against Covid-19. It has been established that stress is a factor that can contribute to the physical and mental overwork and increase immune dysregulation [@bib0110], which would make caregivers even more susceptible to infection.

Recently, India has adopted an anti-viral prophylaxis protocol based on hydroxychloroquine for health professionals [@bib0115]. These recommendations are empiric and are not based on the results of a clinical trial. As of April 15th, 2020, Paris hospitals in France have begun a randomized trial in 900 participants, called PrEP Covid, to access both of HQ and azithromycine in Covid-19 prophylaxis, the trial will access a 200 mg per day posology of HQ, results are expected within 2--3 months [@bib0120].

Chang and Sun recommended safe and potentially efficacious dose regimens for protection against COVID-19 based on a review of chloroquine\'s antiviral mechanisms, its laboratory efficacy activity against COVID-19, as well as its pharmacokinetics in established indications. The authors recommended pre-exposure prophylaxis of 250--500 mg daily and post-exposure prophylaxis at 8 mg/kg/day for 3 days [@bib0105].

An urgent clinical assessment is needed to access the effectiveness of HQ anti Covid-19 chemoprophylaxis, the optimal dosage and the balance between the benefits and risks. Regarding the potential benefits: does anti-viral prophylaxis reduce the risk of infection with Covid-19? In the event of infection, does it reduce the viral carriage and therefore the virus transmissibility? Does it reduce the percentage of serious forms requiring respiratory assistance? And does it reduce mortality among caregivers?

The antiviral prophylaxis study will also need to assess the tolerance profile and side effects of HQ. Regarding this point, there is already evidence of the rarity of serious events after treatment with antimalarial drugs [@bib0125], [@bib0130]. Side effects are infrequent, mild and usually reversible. They include nausea, anorexia, abdominal pain, vomiting, dizziness, headache, blurry vision, and pruritus [@bib0125]. Evaluation should access QT interval prolongation and arrhythmogenic cardiotoxicity. While macular toxicity could be a concern in long term treatment, it seems not to be as a relevant concern in short term prophylactic use [@bib0105], [@bib0135].

It is to be hoped that HQ prophylaxis reduce the morbidity and mortality from Covid-19 infection among caregivers, which are particularly exposed and relatively old. If this chemoprophylaxis is proven to be effective, it could also be interesting to access the indication in persons with Covid-19 high risk of mortality, by individually assessing the risk-benefit balance.
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